UMC, TTUHSC announces groundbreaking findings to shrink tumors, prolong survival in Kidney Cancer patients
A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...
ASCO GU Symposium announces new findings on tumor reduction and survival outcomes in advanced renal cell carcinoma
Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...
Cure Today3d
Cancer Vaccine Elicits Promising Responses in Renal Cell Carcinoma
All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.
Nature4d
Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids
Figure 1: Characterization of the hybrid cell vaccine. The hybrid cell vaccination was well tolerated by all patients. There were no serious adverse effects or any clinical signs of autoimmune ...